Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals A/S) receives USPTO Notice of Allowance for a method of treatment patent on its topical wound-healing composition.
August 15 2023 - 7:54AM
Pharma Equity Group’s subsidiary company (Reponex Pharmaceuticals
A/S) receives USPTO Notice of Allowance for a method of treatment
patent on its topical wound-healing composition.
15 August 2023
Announcement no. 37
Pharma Equity Group’s subsidiary company
(Reponex Pharmaceuticals A/S) receives USPTO Notice of Allowance
for a method of treatment patent on its topical wound-healing
composition.
Reponex Pharmaceuticals A/S (Reponex) today
announced that the United States Patent and Trademark Office
(USPTO) has issued a Notice of Allowance for US patent application
16/366.898. This application describes a method of treating a
chronic wound by the topical application of a hydrogel containing
granulocyte-macrophage colony-stimulating factor (GM-CSF),
sucralfate and hyaluronan to accelerate wound healing.
“Reponex’s treatment combines three active
substances that accelerates the healing of chronic wounds such as
venous and diabetic leg ulcers. We are pleased that the USPTO
intends to grant our patent application for our treatment method,
the USA being such an important commercial area,” says Thomas Kaas
Selsø, CEO of Pharma Equity Group A/S.
According to Grand View Research, the global
wound care market size was valued at USD 21.4 billion in 2022 and
is expected to grow at a compound annual rate (CAGR) of 4.15% from
2023 to 2030. Of this, the market in the USA accounts for approx.
USD 8 billion in 2022. The chronic wounds segment held the largest
share of approx. 60% in 2022.
A Notice of Allowance indicates that the USPTO
intends to grant the application after the completion of standard
procedural steps and the patent is expected to be issued within 1-2
months with validity until 2039.
For further information, please contactThomas
Kaas Selsø, CEOTelephone: +45 4022 2114E-mail:
tks@pharmaequitygroup.com
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the
Nasdaq Copenhagen stock exchange, is fully dedicated to advancing
the medical projects of its subsidiary, Reponex Pharmaceuticals
A/S. With an unwavering focus on healthcare, Pharma Equity Group's
primary objective is to bring significant value to Reponex
Pharmaceuticals' medical projects.
The company is committed to providing extensive
support, resources, and expertise to drive the development and
success of these projects. As a strategic partner, Pharma Equity
Group works closely with Reponex Pharmaceuticals, prioritizing the
advancement of innovative medical solutions and breakthrough
therapies. Every effort is currently directed towards ensuring the
utmost success and impact of Reponex Pharmaceuticals' medical
projects, with an unwavering dedication to improving global
healthcare outcomes. Only when the full potential of Reponex
Pharmaceuticals has been unfolded is the intention to explore
opportunities to invest in other companies. This approach ensures a
strong commitment to the current medical projects and their
development, while – on the longer term – remaining open to new
strategic investments for continuous growth.
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jul 2023 to Jul 2024